lyso-thermosensitive liposomal doxorubicin

DRUG4 trials

Sponsors

National Institutes of Health Clinical Center (CC), Imunon, AeRang Kim, Children's National Research Institute

Conditions

Bone MetastasesColon Cancer Liver MetastasisEwing SarcomaGerm Cell TumorGerm Cell TumorsHepatic TumorLiver CancerMalignant Epithelial Neoplasm

Phase 1

Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors

CompletedNCT00093444

National Institutes of Health Clinical Center (CC)Liver Cancer, Metastatic Cancer

Start: 2004-09-30End: 2010-01-31Target: 30Updated: 2012-03-15

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

TerminatedNCT02536183

AeRang KimEwing Sarcoma, Germ Cell Tumors, Hepatic Tumor +7

Start: 2016-10-31End: 2022-10-31Updated: 2023-08-29

Phase 2

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

TerminatedNCT01464593

ImunonColon Cancer Liver Metastasis

Start: 2011-09-30End: 2013-06-30Updated: 2022-10-13

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

WithdrawnNCT04791228

Children's National Research InstituteBone Metastases, Ewing Sarcoma, Germ Cell Tumor +6

Start: 2022-11-10End: 2024-12-23Updated: 2025-01-01

Related Papers

Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.

2018-07-11150 citations

Phase 1 trial of lyso-thermosensitive liposomal doxorubicin (LTLD) and magnetic resonance guided high intensity focused ultrasound (MR-HIFU) for pediatric refractory solid tumors.

Journal of Clinical Oncology2017-05-208 citations